Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Vaccine vial

Both the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the EU's European Medicines Agency have concluded that whilst there was a possible link from these very rare blood clots to the vaccine, the benefits of vaccination continue to outweigh the risks in all age groups,  and have requested the product information is updated to mitigate further risks.

Both regulators have offered further advice to healthcare professionals, which can be found via the links below: 

Read the full article on the University of Oxford website